ArticleAmerican journal of translational research2023
Prognostic values of Annexins and validation of the influence on cell proliferation, migration, and invasion in uveal melanoma.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy.Nature communications · 2025Article
- UBE2G2 inhibits vasculogenic mimicry and metastasis of uveal melanoma by promoting ubiquitination of LGALS3BP.Acta pharmaceutica Sinica. B · 2024Article
- Annexin A2 combined with TTK accelerates esophageal cancer progression via the Akt/mTOR signaling pathway.Cell death & disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUveal melanoma (UVM), the leading type of intraocular malignant tumor in adults, has an aggressive course with poor prognoses, high mortality, and lacking effective therapeutic targets and prognostic markers. Annexins are well known as dysregulated and correlated with aggressiveness and prognosis of various cancers. However, little is known about the expression pattern of Annexins in UVM and their prognostic value. This study aimed to investigate and verify the role of Annexins in the pathogenesis of metastatic UVM.
methodsThe mRNA expression of Annexins in UVM was analyzed from The Cancer Genome Atlas (TCGA) database and validated in three independent datasets (GSE22138, GSE27831, and GSE156877). The bioinformatics analysis and experimental verification of ANXA2 expression in UVM were performed to evaluate its influence on clinical prognosis, cell proliferation, migration, and invasion.
resultsPrognostic analysis suggested that high ANXA2/4 expression levels were significantly correlated with worse overall survival (OS), progress-free interval (PFI), and metastasis-free survival (MFS) prognoses. Meanwhile, the prognostic model (ANXA2/4) was built using the PFI-based LASSO analysis in TCGA-UVM and validated in GSE22138 and GSE27831. Multivariate Cox regression analyses indicated that the ANXA2/4 model is an independent prognostic factor associated with UVM. The expression analysis confirmed that ANXA2 was upregulated in metastatic patients. Then, ANXA2 mRNA was confirmed positive and expressed higher in four human UVM cell lines compared with ARPE19 cells, especially in two highly invasive metastatic types (C918 and MUM2B). Moreover, silencing ANXA2 blocked cell proliferation, migration, and invasion abilities of C918 and MUM2B while upregulating ANXA2 enhanced these cell functions remarkably in vitro, suggesting that ANXA2 had a positive effect on malignant biological properties of UVM cells. In addition, flow cytometry analysis showed that the knockdown of ANXA2 had a higher apoptotic rate than the control groups in C918 and MUM2B cells. ANXA2 overexpression had a lower apoptotic rate than those in the control group in OCM-1. In addition, ANXA2 expression had significant correlations with the tumor microenvironment and multiple tumor-infiltrating immune cells.
conclusionsANXA2 is a novel potential prognostic biomarker for the metastatic diagnosis of UVM.
Indexed as
Identifiers
37303667PMC10251012W4380291194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.